Navigation Links
InterMune Reports Results from Triple Combination Study of ITMN-191
Date:1/12/2009

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. InterMune to Present at Thomas Weisel Partners Healthcare Conference
2. Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations
3. InterMune to Present at the 2008 Wachovia Healthcare Conference
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage
6. Allscripts Reports Fiscal 2009 Second Quarter Results
7. MDS Reports Final Fourth-Quarter 2008 Results
8. Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $100
9. Cardium Reports on Exchange Listing With NYSE Alternext US
10. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
11. Joint Commission Reports Positive Survey Results for CHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... spending, a new RAND study concludes that U.S. policy ... and device makers to develop products that produce more ... their use, a new study suggests the study identifies ... created in the first place. The aim is to ... of health as possible and to ensure that costlier ...
(Date:4/22/2014)... researchers have demonstrated the first size-based form of ... membranes of living cells. This unique physical approach ... critical to whether a cell lives or dies, ... obtained through conventional microscopy. , "We,ve developed membrane-embedded ... to both probe and manipulate membrane assemblies, including ...
(Date:4/22/2014)... been approved since November 2013 for the prevention and ... an early benefit assessment pursuant to the "Act on ... the German Institute for Quality and Efficiency in Health ... an added benefit over the appropriate comparator therapy. ... turoctocog alfa is not proven. As no relevant study ...
(Date:4/22/2014)... chronic inflammatory disorders of the intestine that result in ... in the U.S., and while there are treatments to ... , Now, Cincinnati Cancer Center and University of Cincinnati ... in her lab have done what is believed to ... important function for the Ron receptor, a cell surface ...
(Date:4/22/2014)... of us have gotten stuck in a check-out line ... Mather, assistant professor of physics and an instructor with ... or queues, has been crucial in trying to understand ... of proteins. , The work, submitted during Mather,s first ... the National Science Foundation in the form of a ...
Breaking Medicine News(10 mins):Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:Two genes linked to inflammatory bowel disease 2Health News:Queuing theory helps physicist understand protein recycling 2
... 15 Theranostics Health (THX) today,announced that ... research,collaboration agreement with Duke University. This relationship ... core technologies: Laser,Capture Microdissection (LCM) and Reverse ... these technologies provides a powerful,mechanism to accurately ...
... Corporation, a,subsidiary of Orthopedic Development Corporation, announced today ... treat chronic facet-oriented back,pain or to supplement other ... of the two facet joints in each spinal ... treat intractable back pain without,precluding other options, has ...
... Health Solutions, Corp.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Mark Thierer,President and COO and Jeff ... Capital Markets 12th Annual Spring Investor Conference at the ... on Thursday, May 29,2008 at 10:30 am Eastern Time., ...
... important as intervention, specialists say , , THURSDAY, May 15 ... such as pacemakers and defibrillators emphasize that they,re just ... very specific statement of the importance of optimized medical ... University of Alabama at Birmingham,s Division of Cardiovascular Disease, ...
... American College of Physicians (ACP) proposed today a ... and use of information about clinical and cost-effectiveness ... The recommendations are featured in an article, Cost-Effectiveness ... Effectiveness Entity, published online today in Annals of ...
... BIRMINGHAM, Ala., May 15 Diagnostic Health Corporation,(DHC), ... the appointment of Robert E. Gontarek as its ... this role, Gontarek will oversee,the operations of DHC,s ... Gontarek joins DHC with nearly 20 years ...
Cached Medicine News:Health News:Theranostics Health Signs Research Collaboration Agreement 2Health News:TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels 2Health News:New Guidelines Issued for Implanted Heart Devices 2Health News:Americans must consider cost and effectiveness when comparing and choosing medical interventions 2Health News:Diagnostic Health Corporation Names Robert E. Gontarek as COO 2
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... A stethoscope adapter for users of ... and socket" type - must send ... are required. , ,Westone custom ... via our worldwide network of hearing ...
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place....
Medicine Products: